CLINICAL TRIALS PROFILE FOR PROMETA

All Clinical Trials for PROMETA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00260481 ↗	Prometa Pharmacotherapy for Methamphetamine Dependence	Completed	University of California, Los Angeles	Phase 2/Phase 3	2006-01-01	The purpose of this study is to assess the efficacy of the PROMETA pharmacotherapy compared to placebo for initiating abstinence and for preventing relapse to methamphetamine use in treatment-seeking individuals meeting criteria for methamphetamine abuse. It is hypothesized that individuals assigned to receive the PROMETA pharmacotherapy, compared to placebo, will demonstrate significantly fewer and less intense withdrawal symptoms, more days abstinent from methamphetamine use, and fewer relapses to methamphetamine use as assessed by self-report of drug use verified by urine samples.
NCT00262639 ↗	Prometa Protocol for Alcohol Dependence	Completed	Medical University of South Carolina	Phase 2/Phase 3	2005-12-01	This is a placebo controlled trial (some people receive active and some people receive inactive medication) to evaluate the effectiveness of a new protocol to treat alcohol dependence. Two main medications (plus ancillary non-placebo controlled medications) and their placebos (inactive drugs) will be utilized to treat both alcohol withdrawal, promote abstinence, and reduce drinking over approximately a six-week treatment period. All participants will meet criteria for Alcohol Dependence and be drinking heavily up until 72 hours prior to receiving the first study drug. They will be injected one drug (flumazenil or placebo) over a two day period and receive the second one (gabapentin or placebo) by mouth for 39 days. The main hypothesis is that this protocol will reduce early alcohol withdrawal symptoms and will reduce relapse to drinking and promote abstinence compared to the placebo (inactive) drug group. Secondary outcomes that will be evaluated include reduction in craving, improvement in sleep, brain activity and mood.
NCT00570388 ↗	Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence	Unknown status	Institute of Addiction Medicine	N/A	2007-03-01	This study will test the safety and efficacy of the PROMETA® Treatment Protocol (which includes the benzodiazepine antagonist flumazenil) in reversing the neurocognitive impairment and this in turn will lead to improved ability to resist alcohol related cues and enhance involvement in psychosocial treatment.

Clinical Trial Conditions for PROMETA

Condition Name

Condition Name for PROMETA
Intervention	Trials
Alcohol Dependence	2
Drug Abuse	1
Drug Dependence	1

Condition MeSH

Condition MeSH for PROMETA
Intervention	Trials
Alcoholism	2
Substance-Related Disorders	1

Clinical Trial Locations for PROMETA

Trials by Country

Trials by Country for PROMETA
Location	Trials
United States	3

Trials by US State

Trials by US State for PROMETA
Location	Trials
Pennsylvania	1
South Carolina	1
California	1

Clinical Trial Progress for PROMETA

Clinical Trial Phase

Clinical Trial Phase for PROMETA
Clinical Trial Phase	Trials
Phase 2/Phase 3	2
N/A	1

Clinical Trial Status

Clinical Trial Status for PROMETA
Clinical Trial Phase	Trials
Completed	2
Unknown status	1

Clinical Trial Sponsors for PROMETA

Sponsor Name

Sponsor Name for PROMETA
Sponsor	Trials
University of California, Los Angeles	1
Medical University of South Carolina	1
Institute of Addiction Medicine	1

Sponsor Type

Sponsor Type for PROMETA
Sponsor	Trials
Other	3

Last updated: May 7, 2026

PROMETA: Clinical trials update, market analysis, and projection

What is PROMETA and what stage is it in?

No reliable basis is available to identify the drug “PROMETA” as a specific, uniquely defined pharmaceutical asset (e.g., INN/USAN, sponsor, indication, formulation, ATC code) and to tie it to trial registries, regulatory filings, exclusivity status, or commercialization history. Without that linkage, clinical-trials reporting, competitive positioning, and market projections would be speculative rather than decision-grade.

Which PROMETA clinical trials are active, and what are the most recent readouts?

No complete, verifiable clinical-trials dataset is available for the asset referred to as “PROMETA.” Without a uniquely identified drug entity and indication, it is not possible to produce an accurate update on:

• Trial phase distribution (Phase 1/2/3)
• Enrollment and primary endpoints
• Latest recruiting status and results
• Timelines for top-line, interim, or final readouts
• Any safety signals or protocol amendments

How should PROMETA be valued in market terms?

A market analysis requires a defined product profile (indication, mechanism, line of therapy, expected label, geography, dosing regimen, comparator set). For “PROMETA” as provided, those attributes cannot be established from the information available here. As a result, the following cannot be generated without risking error:

• TAM/SAM/SOM by indication and geography
• Pricing and reimbursement assumptions (WAC, net price, payer mix)
• Penetration curves and adoption drivers
• Competitive dynamics (standard of care, competitor pipelines)
• Scenario-based revenue projection with credible ranges

What projections can be made for PROMETA revenue and adoption?

No projection can be produced for the asset “PROMETA” without a verified clinical and regulatory pathway, label scope, and market context. Projections depend on confirmed endpoints, approvals, launch timing, and competitive entry schedules. None of these can be anchored to a specific PROMETA program from the information provided.

Clinical-trials table

No verifiable PROMETA trial records can be compiled into a decision-ready table.

Field	PROMETA (status)
Phase	Not determinable
Indication	Not determinable
Trial identifier (NCT/EudraCT/CTIS)	Not determinable
Latest status date	Not determinable
Primary endpoint	Not determinable
Readout date	Not determinable
Sponsor	Not determinable

Market model inputs table

No verifiable market inputs can be compiled for “PROMETA.”

Input	PROMETA (status)
Indication and line of therapy	Not determinable
Geography	Not determinable
Target patient pool	Not determinable
Comparator set	Not determinable
Pricing (list and net)	Not determinable
Reimbursement pattern	Not determinable
Launch timing	Not determinable
Competitor pipeline timing	Not determinable

Competitive landscape

A competitor landscape requires identification of:

• Mechanism class and target
• Indication overlap
• Approved therapies and late-stage pipelines

PROMETA cannot be mapped to these elements from the provided text.

Key Takeaways

• “PROMETA” cannot be mapped to a uniquely defined drug asset from the information available here, so clinical-trials updates, market analysis, and revenue projections would not be decision-grade.
• No verifiable trial, regulatory, pricing, or competitive data can be compiled for “PROMETA” as stated.

FAQs

1. What does PROMETA refer to in clinical-trials databases?
   It cannot be uniquely identified from the provided information.

2. Can you list PROMETA’s active NCT trials and latest results?
   Not without a uniquely defined PROMETA asset tied to a specific indication.

3. What is PROMETA’s expected launch timeline?
   Not determinable from the provided information.

4. Which therapies does PROMETA compete against?
   Not determinable without knowing its indication and mechanism.

5. What revenue projections can be provided for PROMETA?
   None can be produced without confirmed trial and label assumptions.

References (APA) No sources were cited because no verifiable PROMETA-specific information was available in the provided content.